Experimental animal models for development of human enterovirus vaccine.

Disease models Enterovirus Vaccines

Journal

Clinical and experimental vaccine research
ISSN: 2287-3651
Titre abrégé: Clin Exp Vaccine Res
Pays: Korea (South)
ID NLM: 101592344

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 25 08 2023
revised: 26 08 2023
accepted: 26 08 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: ppublish

Résumé

Enterovirus infections induce infectious diseases in young children, such as hand, foot, and mouth disease which is characterized by highly contagious rashes or blisters around the hands, feet, buttocks, and mouth. This predominantly arises from enterovirus A71 or coxsackievirus A16 infections and in severe cases, they can lead to encephalitis, paralysis, pulmonary edema, or even fatality, representing a global health threat. Due to the absence of effective therapeutic strategies for these infections, various experimental animal models are being investigated for the development of vaccines. During the early stages of research on enterovirus infections, non-human primate infections exhibited symptoms like those in humans, leading to their utilization as model animals. However, due to economic and ethical considerations, their current usage is limited. While enterovirus infections do not readily occur in mice, an infection model with mouse-adapted strain in neonatal mice has been employed. Cellular receptors have been identified in human cells, and genetically modified mice expressing these receptors have been used. Most recently, the utilization of Mongolian gerbil model is actively being considered and should be pursued for further animal model development. So, herein, we provide a summarized overview of the current portfolio of available enterovirus infection models, emphasizing their respective advantages and limitations.

Identifiants

pubmed: 38025911
doi: 10.7774/cevr.2023.12.4.291
pmc: PMC10655152
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

291-297

Informations de copyright

© Korean Vaccine Society.

Déclaration de conflit d'intérêts

No potential conflict of interest relevant to this article was reported.

Références

Emerg Microbes Infect. 2022 Dec;11(1):1994-2006
pubmed: 35787233
J Virol. 2001 Aug;75(16):7732-8
pubmed: 11462047
Lab Invest. 2011 Sep;91(9):1337-50
pubmed: 21555996
Emerg Microbes Infect. 2018 Nov 21;7(1):185
pubmed: 30459302
J Virol. 2014 Nov;88(21):12485-99
pubmed: 25142603
J Gen Virol. 2013 May;94(Pt 5):1019-1027
pubmed: 23288420
Nat Med. 2009 Jul;15(7):798-801
pubmed: 19543282
J Med Virol. 2002 Jun;67(2):207-16
pubmed: 11992581
Arch Virol. 1979;60(3-4):329-40
pubmed: 228639
Crit Rev Microbiol. 2011 Nov;37(4):313-27
pubmed: 21651436
PLoS One. 2012;7(12):e51996
pubmed: 23284845
PLoS One. 2013;8(2):e57591
pubmed: 23451246
World J Gastroenterol. 2015 Jan 21;21(3):862-7
pubmed: 25624719
J Virol. 2011 Nov;85(22):11809-20
pubmed: 21900167
Arch Virol. 2012 Jan;157(1):37-41
pubmed: 21984267
Sci Rep. 2016 Aug 08;6:31151
pubmed: 27499235
Arch Virol. 1978;56(3):257-61
pubmed: 205198
Infect Immun. 1981 Oct;34(1):26-9
pubmed: 6271682
Vaccine. 2015 Nov 27;33(48):6604-10
pubmed: 26529069
Int J Infect Dis. 2019 Mar;80:1-9
pubmed: 30550944
PLoS Pathog. 2008 Feb 8;4(2):e29
pubmed: 18282093
J Infect Dis. 2008 Oct 1;198(7):1002-6
pubmed: 18710325
Expert Opin Biol Ther. 2014 Oct;14(10):1455-64
pubmed: 24989170
Virol J. 2022 Dec 1;19(1):203
pubmed: 36457099
Clin Exp Immunol. 2012 Apr;168(1):47-51
pubmed: 22385236
Arch Virol. 2012 Mar;157(3):539-43
pubmed: 22187102
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14753-8
pubmed: 23959904
PLoS One. 2015 Mar 13;10(3):e0119173
pubmed: 25767882
Neuropathol Appl Neurobiol. 1982 Mar-Apr;8(2):149-56
pubmed: 7048123
Virol J. 2009 Sep 15;6:141
pubmed: 19751532
Virology. 2012 Jan 5;422(1):132-43
pubmed: 22078110
Am J Trop Med Hyg. 1996 Oct;55(4):384-90
pubmed: 8916793
J Virol. 2007 Sep;81(17):9386-95
pubmed: 17567701
J Virol. 2004 Aug;78(15):7916-24
pubmed: 15254164
Biomol Ther (Seoul). 2023 May 1;31(3):350-358
pubmed: 37041034
Antiviral Res. 2016 Oct;134:207-215
pubmed: 27623347
Clin Infect Dis. 2001 Jan 15;32(2):236-42
pubmed: 11170913
Clin Infect Dis. 2000 Sep;31(3):678-83
pubmed: 11017815
J Clin Microbiol. 2009 Sep;47(9):2826-33
pubmed: 19625480
Virology. 2011 Mar 30;412(1):91-100
pubmed: 21262515
Proc Soc Exp Biol Med. 1955 Nov;90(2):529-31
pubmed: 13273503
Nat Struct Mol Biol. 2012 Mar 04;19(4):424-9
pubmed: 22388738
Arch Virol. 2016 Nov;161(11):3073-80
pubmed: 27518403
J Virol. 2016 Sep 12;90(19):8592-604
pubmed: 27440896
J Neurovirol. 2012 Oct;18(5):374-87
pubmed: 22825914
Emerg Infect Dis. 2012 Dec;18(12):2002-5
pubmed: 23194699
J Gen Virol. 2004 Jan;85(Pt 1):69-77
pubmed: 14718621
PLoS One. 2018 Dec 13;13(12):e0203792
pubmed: 30543631
Emerg Microbes Infect. 2016 Sep 21;5(9):e104
pubmed: 27651091
J Gen Virol. 2005 May;86(Pt 5):1391-1401
pubmed: 15831951
Nat Med. 2009 Jul;15(7):794-7
pubmed: 19543284
Viruses. 2015 Jul 17;7(7):3891-909
pubmed: 26193302
Nat Commun. 2017 Feb 21;8:14575
pubmed: 28220786
J Gen Virol. 2008 Jul;89(Pt 7):1622-1632
pubmed: 18559932
mSphere. 2020 Jul 1;5(4):
pubmed: 32611697
J Virol. 2013 Jan;87(1):611-20
pubmed: 23097443
Front Microbiol. 2018 Aug 14;9:1866
pubmed: 30154774
J Virol. 2012 Feb;86(4):2121-31
pubmed: 22130542
Arch Virol. 2003 Jul;148(7):1369-85
pubmed: 12827466
J Gen Virol. 2004 Oct;85(Pt 10):2981-2989
pubmed: 15448361
Emerg Microbes Infect. 2018 Jan 24;7(1):8
pubmed: 29362406

Auteurs

Jae Min Song (JM)

School of Biopharmaceutical and Medical Sciences, Sungshin Women's University, Seoul, Korea.

Classifications MeSH